Nervianos Aurora kinase effective and safe in Phase I

Data presented at the EORTC-NCI-AACR Symposium show Nerviano’s Aurora kinase inhibitor PHA 739358 to demonstrate good tolerability early signs of efficacy

GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

Exelixis PI3K Inhibitor XL147 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit ‘robust pharmacodynamics’ and preliminary clinical benefit

Exelixis Raf kinase inhibitor XL281 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis RAF kinase inhbitor XL281 to show early signs of clinical activity

EntreMeds Aurora A inhibitor ENMD-2076 effective in vivo

Data presented at the EORTC-NCI-AACR Annual Meeting show EntreMed’ Aurora A kinase inhibitor ENMD-2076 to demonstrate strong antitumor effects in a xenograft model of human colon cancer.

Phase III Avastin trial in Colon Cancer to continue

Genentech have announced that its ongoing Phase III study of Avastin (bevacizumab) in patients with early-stage colon cancer will continue as planned.

ARIAD begin Phase II study of Deforolimus in Prostate Cancer

ARIAD/Merck have initiated a Phase II clinical trial to evaluate the safety and efficacy of mTOR inhibitor deforolimus in patients with advanced prostate cancer.

ARIAD to present data on Deforolimus and AP24534 at EORTC-NCI-AACR

ARIAD will present new data on mTOR inhibitor deforolimus, and multikinase inhibitor AP24534 at the EORTC-NCI-AACR meeting:
Abstract 195/321/324 – deforolimus
Abstract 553 – AP24534

Ardea initiate Phase I/II trial of MEK inhibitor RDEA119

Ardea Biosciences has initiated a Phase I/II study of MEK inhibitor RDEA119, in patients with advanced cancer

AstraZeneca publish series of B-Raf Kinase inhibitors

AstraZeneca have publsihed a series of amidoheteroaryl B-Raf Kinase inhibitors